\-\ Texto\\:\\ \ \(0\)\
\-\ treatment\\ consists\\ of\\ nephrectomy\\ and\\ lymph\\ node\\ exploration\\.\\ \\ depending\\ on\\ stage\\,\\ numerous\\ clinical\\ trials\\ are\\ available\\.\ \(0\)\
\-\ http\\:\\/\\/www\\.cancer\\.gov\\/cancertopics\\/pdq\\/treatment\\/renalcell\\/healthprofessional\ \(0\)\
\-\ mri\\ images\\ demonstrate\\ a\\ 3cm\\ solid\\ mass\\ in\\ the\\ upper\\ pole\\ of\\ the\\ right\\ kidney\\.\\ \\ the\\ mass\\ is\\ low\\ signal\\ intensity\\ relative\\ to\\ renal\\ parenchyma\\ on\\ t2\\ and\\ intermediate\\ signal\\ on\\ t1\\.\\ \\ on\\ post\\-gadolinium\\ images\\ there\\ is\\ mild\\,\\ heterogeneous\\ enhancement\\.\ \(0\)\
\-\ renal\\ cell\\ carcinoma\ \(60\)\
\-\ renal\\ cell\\ carcinoma\ \(60\)\
\-\ oncocytoma\ \(13\)\
\-\ lymphoma\ \(373\)\
\-\ metastatic\\ disease\\.\ \(69\)\
\-\ 57\\ y\\/o\\ male\\ with\\ hypertension\\ referred\\ for\\ mra\\ of\\ renal\\ arteries\\ after\\ elevated\\ velocities\\ found\\ on\\ renal\\ artery\\ ultrasound\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ renal\\:\\ 0\\.3987680436220454\ \(0\)\
\-\ on\\:\\ 0\\.19339863329424073\ \(0\)\
\-\ velocities\\:\\ 0\\.1766875121258518\ \(0\)\
\-\ trials\\:\\ 0\\.15957635669455772\ \(0\)\
\-\ carcinoma\\:\\ 0\\.15321290917583744\ \(0\)\
\-\ cell\\:\\ 0\\.1465253522201364\ \(0\)\
\-\ exploration\\:\\ 0\\.14637968902623363\ \(0\)\
\-\ oncocytoma\\:\\ 0\\.145563182387583\ \(0\)\
\-\ signal\\:\\ 0\\.14519994153454274\ \(0\)\
\-\ 3cm\\:\\ 0\\.13393460477902486\ \(0\)\
\-\ nephrectomy\\:\\ 0\\.13081752415709924\ \(0\)\
\-\ intermediate\\:\\ 0\\.13081752415709924\ \(0\)\
\-\ consists\\:\\ 0\\.12735661663061543\ \(0\)\
\-\ mra\\:\\ 0\\.126654951460171\ \(0\)\
\-\ treatment\\:\\ 0\\.12201429833516264\ \(0\)\
\-\ depending\\:\\ 0\\.12199314496563832\ \(0\)\
\-\ 57\\:\\ 0\\.12089773463996481\ \(0\)\
\-\ images\\:\\ 0\\.1184829925822468\ \(0\)\
\-\ relative\\:\\ 0\\.11345828379184693\ \(0\)\
\-\ pole\\:\\ 0\\.11161696895514484\ \(0\)\
\-\ node\\:\\ 0\\.11007976702968668\ \(0\)\
\-\ numerous\\:\\ 0\\.10818133037683458\ \(0\)\
\-\ parenchyma\\:\\ 0\\.10403743609868933\ \(0\)\
\-\ stage\\:\\ 0\\.10198950371255282\ \(0\)\
\-\ arteries\\:\\ 0\\.10164672670198734\ \(0\)\
\-\ lymph\\:\\ 0\\.09958949234955392\ \(0\)\
\-\ solid\\:\\ 0\\.09818581917550352\ \(0\)\
\-\ hypertension\\:\\ 0\\.09799227092441586\ \(0\)\
\-\ mass\\:\\ 0\\.09783962466521924\ \(0\)\
\-\ referred\\:\\ 0\\.09476660424796896\ \(0\)\
\-\ http\\:\\ 0\\.09468329633018698\ \(0\)\
\-\ heterogeneous\\:\\ 0\\.09269514344173942\ \(0\)\
\-\ intensity\\:\\ 0\\.09093908588906123\ \(0\)\
\-\ kidney\\:\\ 0\\.08997476461986703\ \(0\)\
\-\ elevated\\:\\ 0\\.08730790104073319\ \(0\)\
\-\ available\\:\\ 0\\.08689267069392961\ \(0\)\
\-\ found\\:\\ 0\\.08286795985170096\ \(0\)\
\-\ clinical\\:\\ 0\\.081165560459793\ \(0\)\
\-\ t1\\:\\ 0\\.07979641418653147\ \(0\)\
\-\ artery\\:\\ 0\\.07954079710184175\ \(0\)\
\-\ ultrasound\\:\\ 0\\.07899674633358164\ \(0\)\
\-\ the\\:\\ 0\\.07666458649034119\ \(0\)\
\-\ lymphoma\\:\\ 0\\.0762743809536756\ \(0\)\
\-\ of\\:\\ 0\\.07518895135720925\ \(0\)\
\-\ enhancement\\:\\ 0\\.07371560272836244\ \(0\)\
\-\ t2\\:\\ 0\\.07368294605630342\ \(0\)\
\-\ low\\:\\ 0\\.07348799729382278\ \(0\)\
\-\ mild\\:\\ 0\\.07259997076727137\ \(0\)\
\-\ metastatic\\:\\ 0\\.0702406936684768\ \(0\)\
\-\ is\\:\\ 0\\.0701463835375366\ \(0\)\
\-\ upper\\:\\ 0\\.06843931176435061\ \(0\)\
\-\ demonstrate\\:\\ 0\\.06658071179211408\ \(0\)\
\-\ mri\\:\\ 0\\.06574043441743434\ \(0\)\
\-\ after\\:\\ 0\\.062129480266544315\ \(0\)\
\-\ male\\:\\ 0\\.0570222631781793\ \(0\)\
\-\ disease\\:\\ 0\\.05375977606528903\ \(0\)\
\-\ and\\:\\ 0\\.05292872653227956\ \(0\)\
\-\ there\\:\\ 0\\.0509591672055253\ \(0\)\
\-\ are\\:\\ 0\\.04859722836245002\ \(0\)\
\-\ right\\:\\ 0\\.04246093034195901\ \(0\)\
\-\ for\\:\\ 0\\.03881742385883666\ \(0\)\
\-\ to\\:\\ 0\\.0320175699116399\ \(0\)\
\-\ in\\:\\ 0\\.03185997949884547\ \(0\)\
\-\ with\\:\\ 0\\.025077958912576213\ \(0\)\
